Regeneron Pharmaceuticals (REGN) announced earnings for fourth quarter that decreased from last year but beat the Street estimates.
The company's bottom line totaled $1.16 billion, or $10.19 per share. This compares with $1.20 billion, or $10.50 per share, in last year's fourth quarter.
Excluding items, Regeneron Pharmaceuticals reported adjusted earnings of $1.37 billion or $11.86 per share for the period.
Analysts on average had expected the company to earn $10.77 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter rose 0.6% to $3.43 billion from $3.41 billion last year.
Regeneron Pharmaceuticals earnings at a glance (GAAP) :
-Earnings (Q4): $1.16 Bln. vs. $1.20 Bln. last year.
-EPS (Q4): $10.19 vs. $10.50 last year.
-Analyst Estimates: $10.77
-Revenue (Q4): $3.43 Bln vs. $3.41 Bln last year.
For comments and feedback: editorial@rttnews.com